Longitudinal changes in anger, anxiety, and fatigue are associated with cerebrospinal fluid biomarkers of Alzheimers disease
Mitochondrion 13 , 170188, (2013)
The study discussed here was relatively small, involving only 17 patients, and more extensive clinical trials are needed to fully understand: Long-term safety profile Optimal dosing protocols Patient selection criteria Potential side effects Interactions with other treatments Additionally, patients should be aware that BPC-157 is not yet FDA-approved for human use, and treatment is typically offered on a research or compassionate use basis by qualified practitioners
Comparison conditions were as follows: 0 month, accelerated 6 month test
These trials allow manufacturers to make specific and regulated health claims and provide doctors with guidelines about risks, side effects and who might be a viable candidate for the drug